Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

53.95 -0.34 (-0.63%)
Streaming Delayed Price Updated: 10:03 AM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Praxis Precision Medicines, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
From Pomerantz LLP
Via GlobeNewswire
Praxis Precision Medicines to Participate in September Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Praxis, Align, Lantheus, and Spirit and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
From Pomerantz LLP
Via GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
From Pomerantz LLP
Via GlobeNewswire
PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
From Pomerantz LLP
Via GlobeNewswire
PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Praxis Precision Medicines, Inc. - PRAX
From Pomerantz LLP
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.